Zobrazeno 1 - 10
of 161
pro vyhledávání: '"Antineoplastic Agents/*administration & dosage"'
The Implementation of a PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy) Program in Portugal
Publikováno v:
Acta Médica Portuguesa (2022)
N/a.
Externí odkaz:
https://doaj.org/article/91324f25ddd54cc497f60654a6dae740
Autor:
Barbara Eichhorst, Carsten U. Niemann, Arnon P. Kater, Moritz Fürstenau, Julia von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Caspar da Cunha-Bang, Christof Schneider, Christian B. Poulsen, Thomas Illmer, Björn Schöttker, Thomas Nösslinger, Ann Janssens, Ilse Christiansen, Michael Baumann, Henrik Frederiksen, Marjolein van der Klift, Ulrich Jäger, Maria B.L. Leys, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry Koene, Lisbeth Enggaard, Jereon Goede, Josien C. Regelink, Anouk Widmer, Florian Simon, Nisha De Silva, Anna-Maria Fink, Jasmin Bahlo, Kirsten Fischer, Clemens-Martin Wendtner, Karl A. Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark-David Levin, Marinus van Oers, Christian Geisler, Stephan Stilgenbauer, Michael Hallek
Publikováno v:
Eichhorst, B, Niemann, C U, Kater, A P, Fürstenau, M, von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, P B, Tadmor, T, Lindström, V, da Cunha-Bang, C, Schneider, C, Poulsen, C B, Illmer, T, Schöttker, B, Nösslinger, T, Janssens, A, Christiansen, I, Baumann, M, Frederiksen, H, van der Klift, M, Jäger, U, Leys, M B L, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, H, Enggaard, L, Goede, J, Regelink, J C, Widmer, A, Simon, F, De Silva, N, Fink, A-M, Bahlo, J, Fischer, K, Wendtner, C-M, Kreuzer, K A, Ritgen, M, Brüggemann, M, Tausch, E, Levin, M-D, van Oers, M, Geisler, C, Stilgenbauer, S, Hallek, M, German CLL Study Group (GCLLSG), Haemato-Oncology Foundation for Adults in the Netherlands (HOVON), Nordic CLL Study Groups, Swiss Group for Clinical Cancer Research (SAKK), The Israeli CLL Association & Cancer Trials Ireland 2023, ' First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia ', The New England Journal of Medicine, vol. 388, no. 19, pp. 1739-1754 . https://doi.org/10.1056/NEJMoa2213093
BACKGROUNDRandomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking.METHODSIn a phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57065540dd32adf0cc1d031449d13807
https://vbn.aau.dk/da/publications/3cae35e7-c81b-42b3-8598-001ac74af83e
https://vbn.aau.dk/da/publications/3cae35e7-c81b-42b3-8598-001ac74af83e
Autor:
Charlotte Maggen, Ingrid A. Boere, Elyce Cardonick, Liesbeth Lenaerts, Joosje Heimovaara, Vera E. R. A. Wolters, Frédéric Amant
Publikováno v:
International Journal of Gynecological Cancer
International Journal of Gynecological Cancer, 31(3), 314-322. BMJ Publishing Group
International Journal of Gynecological Cancer, 31(3), 314-322. BMJ Publishing Group
As the incidence of cancer in pregnancy has been increasing in recent decades, more specialists are confronted with a complex oncologic–obstetric decision-making process. With the establishment of (inter)national registries, including the Internati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3fa89aab9fad6538cc5b6ca3917d6d1
https://doi.org/10.1136/ijgc-2020-001776
https://doi.org/10.1136/ijgc-2020-001776
Autor:
Maximilian Merz, Anna Jauch, Peter Brossart, Jan Duerig, Hartmut Goldschmidt, Dirk Hose, Steffen Luntz, Britta Besemer, Elias K. Mai, Ahmet H. Elmaagacli, Anja Seckinger, Markus Munder, Stephan Fuhrmann, Hans-Walter Lindemann, Uta Bertsch, Marc S. Raab, Igor Wolfgang Blau, Christian Jehn, Hans Salwender, Katja Weisel, Axel Benner, Kaya Miah, Mathias Haenel, Christof Scheid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c3e93f399758e8aa52c01b85b8ed62d
https://hdl.handle.net/20.500.14017/a78230dc-1b15-42b4-b98b-770e800164f1
https://hdl.handle.net/20.500.14017/a78230dc-1b15-42b4-b98b-770e800164f1
Autor:
Liu, Peng, Zhao, Liwei, Pol, Jonathan, Levesque, Sarah, Petrazzuolo, Adriana, Pfirschke, Christina, Engblom, Camilla, Rickelt, Steffen, Yamazaki, Takahiro, Iribarren, Kristina, Senovilla, Laura, Bezu, Lucillia, Vacchelli, Erika, Sica, Valentina, Melis, Andréa, Martin, Tiffany, Lin, Xia, Yang, Heng, Li, Qingqing, Chen, Jinfeng, Durand, Sylvère, Aprahamian, Fanny, Lefevre, Deborah, Broutin, Sophie, Paci, Angelo, Bongers, Amaury, Minard-Colin, Veronique, Tartour, Eric, Zitvogel, Laurence, Apetoh, Lionel, Ma, Yuting, Pittet, Mikael J., Kepp, Oliver, Kroemer, Guido
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-17 (2019)
Nature Communications
Nature Communications, Nature Publishing Group, 2019, 10, pp.1486. ⟨10.1038/s41467-019-09415-3⟩
Nature Communications, Vol. 10, No 1 (2019) P. 1486
Nature Communications
Nature Communications, Nature Publishing Group, 2019, 10, pp.1486. ⟨10.1038/s41467-019-09415-3⟩
Nature Communications, Vol. 10, No 1 (2019) P. 1486
Immunogenic cell death (ICD) converts dying cancer cells into a therapeutic vaccine and stimulates antitumor immune responses. Here we unravel the results of an unbiased screen identifying high-dose (10 µM) crizotinib as an ICD-inducing tyrosine kin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::ed0d8ca6cf5c1e35474efa37860411f6
http://link.springer.com/article/10.1038/s41467-019-09415-3
http://link.springer.com/article/10.1038/s41467-019-09415-3
Autor:
Jonas Abrahamsson, Hanne Vibeke Marquart, Kjeld Schmiegelow, Benjamin Ole Wolthers, Goda Vaitkeviciene, Bendik Lund, Sofie Gottschalk Højfeldt, Thomas Frandsen, Kim Vettenranta, Kathrine Grell, Birgitte Klug Albertsen, Olafur G. Jonsson, Mats Heyman, Kristi Lepik
Publikováno v:
Gottschalk Højfeldt, S, Grell, K, Abrahamsson, J, Lund, B, Vettenranta, K, Jonsson, O G, Frandsen, T L, Wolthers, B O, Marquart, H V H, Vaitkeviciene, G, Lepik, K, Heyman, M, Schmiegelow, K & Albertsen, B K 2021, ' Relapse risk following truncation of PEG-asparaginase in childhood acute lymphoblastic leukemia ', Blood, vol. 137, no. 17, pp. 2373–2382 . https://doi.org/10.1182/blood.2020006583
Gottschalk Højfeldt, S, Grell, K, Abrahamsson, J, Lund, B, Vettenranta, K, Jonsson, O G, Frandsen, T L, Wolthers, B O, Marquart, H V H, Vaitkeviciene, G, Lepik, K, Heyman, M, Schmiegelow, K, Albertsen, B K & Nordic Society of Pediatric Hematology and Oncology, NOPHO Group 2021, ' Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia ', Blood, vol. 137, no. 17, pp. 2373-2382 . https://doi.org/10.1182/blood.2020006583
Gottschalk Højfeldt, S, Grell, K, Abrahamsson, J, Lund, B, Vettenranta, K, Jonsson, O G, Frandsen, T L, Wolthers, B O, Marquart, H V H, Vaitkeviciene, G, Lepik, K, Heyman, M, Schmiegelow, K, Albertsen, B K & Nordic Society of Pediatric Hematology and Oncology, NOPHO Group 2021, ' Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia ', Blood, vol. 137, no. 17, pp. 2373-2382 . https://doi.org/10.1182/blood.2020006583
Truncation of asparaginase treatment due to asparaginase-related toxicities or silent inactivation (SI) is common and may increase relapse risk in acute lymphoblastic leukemia (ALL). We investigated relapse risk following suboptimal asparaginase expo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d808bc1a2b93ba78630627eeaf03189
https://curis.ku.dk/portal/da/publications/relapse-risk-following-truncation-of-pegasparaginase-in-childhood-acute-lymphoblastic-leukemia(14ed586e-290f-4739-a892-505c135ea2e7).html
https://curis.ku.dk/portal/da/publications/relapse-risk-following-truncation-of-pegasparaginase-in-childhood-acute-lymphoblastic-leukemia(14ed586e-290f-4739-a892-505c135ea2e7).html
Autor:
Kang Yell Choi, Jong Chan Park, Jeong Su Yoon, Yong Hee Cho, Dong Woo Kang, Eun Ji Ro, Hans Clevers, Tae Il Kim, Tomohiro Mizutani
Publikováno v:
Nature Communications, 11(1). Nature Publishing Group
Nature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
Nature Communications
5-Fluorouracil (5-FU) remains the first-line treatment for colorectal cancer (CRC). Although 5-FU initially de-bulks the tumor mass, recurrence after chemotherapy is the barrier to effective clinical outcomes for CRC patients. Here, we demonstrate th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5c3cd05c8716e3e7fd22f0717726d0f
https://hdl.handle.net/20.500.11755/de483e27-9a68-49de-bf37-80bb92ac9c00
https://hdl.handle.net/20.500.11755/de483e27-9a68-49de-bf37-80bb92ac9c00
Publikováno v:
Vestergaard Madsen, C, Adimi, P, Jakobsen, A & Dahl Steffensen, K 2020, ' Cabazitaxel-Α treatment option in recurrent platinum-resistant ovarian cancer ', Anticancer Research, vol. 40, no. 9, pp. 5255-5261 . https://doi.org/10.21873/anticanres.14529
Madsen, C V, Adimi, P, Jakobsen, A & Dahl Steffensen, K 2018, ' CABAZITAXEL-A TREATMENT OPTION IN RECURRENT PLATINUM-RESISTANT OVARIAN CANCER ', 17th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2018), Kyoto, Japan, 14/09/2018-16/09/2018 . < https://igcs2018.com/scientific-information/interactive-program#.W7R11dTU-70 >
University of Southern Denmark
Madsen, C V, Adimi, P, Jakobsen, A & Dahl Steffensen, K 2018, ' CABAZITAXEL-A TREATMENT OPTION IN RECURRENT PLATINUM-RESISTANT OVARIAN CANCER ', 17th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2018), Kyoto, Japan, 14/09/2018-16/09/2018 . < https://igcs2018.com/scientific-information/interactive-program#.W7R11dTU-70 >
University of Southern Denmark
Background and Aims:Treatment of recurrent platinum-resistant ovarian cancer remains challenging due to the development of chemo-resistance. Cabazitaxel is a new taxane that has demonstrated effect in prostatic cancer patients resistant to Docetaxel.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5cf13075695ccbe7745d4b757267d78
https://portal.findresearcher.sdu.dk/da/publications/90e952c0-9af8-4e25-8bf2-3431eeb1752f
https://portal.findresearcher.sdu.dk/da/publications/90e952c0-9af8-4e25-8bf2-3431eeb1752f
Autor:
Alwin D. R. Huitema, Hilde Rosing, Niels de Vries, Jan H.M. Schellens, Dick Pluim, Bart A. W. Jacobs, Bastiaan Nuijen, Jeroen Roosendaal, Erik van Werkhoven, Serena Marchetti, Jos H. Beijnen
Publikováno v:
Pharmaceutical Research
Pharmaceutical Research, 37(5). Springer New York LLC
Pharmaceutical research, 37(5):89. Springer New York
Pharmaceutical Research, 37(5). Springer New York LLC
Pharmaceutical research, 37(5):89. Springer New York
Purpose Capecitabine is an oral pre-pro-drug of the anti-cancer drug 5-fluorouracil (5-FU). The biological activity of the 5-FU degrading enzyme, dihydropyrimidine dehydrogenase (DPD), and the target enzyme thymidylate synthase (TS), are subject to c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1a72e841bba8beccd52150f77953495
https://dspace.library.uu.nl/handle/1874/410999
https://dspace.library.uu.nl/handle/1874/410999
Autor:
Tessmann, Luiza, Medeiros-Souza, Patrícia, Martins Cordoba, José Carlos, Urruth Leão Tavares, Noemia, Macedo Abílio, Victória, Oliveira de Matos, Dafny, Quezado Soares Magalhães, Isis Maria
Publikováno v:
Revista Brasileira de Cancerologia; Vol. 66 No. 2 (2020): Apr./May/June; e-01764
Revista Brasileira de Cancerologia; Vol. 66 Núm. 2 (2020): abr./mayo/jun.; e-01764
Revista Brasileira de Cancerologia; v. 66 n. 2 (2020): abr./maio/jun.; e-01764
Revista Brasileira de Cancerologia
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
Revista Brasileira de Cancerologia; Vol. 66 Núm. 2 (2020): abr./mayo/jun.; e-01764
Revista Brasileira de Cancerologia; v. 66 n. 2 (2020): abr./maio/jun.; e-01764
Revista Brasileira de Cancerologia
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
Introduction: Antineoplastic drug manipulation for dose adjustment, such as tablet splitting, is standard in acute leukemia treatment for children and adolescents. Objective: To identify the frequency and describe the practice of household splitting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3056::e5c1648f5079577047d980960f389281
https://rbc.inca.gov.br/index.php/revista/article/view/764
https://rbc.inca.gov.br/index.php/revista/article/view/764